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FRENCH ABSTRACT 
 
Introduction: Le gène O6-méthylguanine-ADN méthyltransferase (MGMT) code pour 
une enzyme spécifique réparatrice de l’ADN qui protège les cellules de la toxicité des 
agents alkylants. Ainsi, l’activité du MGMT est un mécanisme majeur de résistance 
aux agents alkylants. Il a été démontré qu’une diminution de l’expression du gène 
MGMT par une hyperméthylation du promoteur résulte en une amélioration de la 
survie chez les patients avec certains types de tumeurs qui sont traitées avec des 
agents chimiothérapeuthique alkylants. Objectifs: Déterminer la prévalence de la 
méthylation du gène MGMT chez des patients avec des cancers épidermoïdes 
localement avancés de la sphère ORL traités avec chimioradiothérapie et évaluer 
l’impact de cette méthylation sur la survie.  Méthodes: Sur 428 patients consécutifs, 
traités avec chimioradiothérapie à notre institution et suivis pour un période médiane 
de 37 mois, 199 spécimens chirurgicaux paraffinés ont été récupérés. L’ADN était 
extrait et modifié par le traitement au bisulfite. Une réaction en chaîne de la 
polymérase, spécifique à la méthylation était entreprise pour évaluer l’état de 
méthylation du promoteur du gène du MGMT. Les résultats de laboratoire étaient 
corrélés avec la réponse clinique. L’analyse statistique était exécutée à l’aide du test 
de Fisher pour les données catégoriques et à l’aide des courbes de Kaplan-Meier pour 
les échecs au traitement.  Résultats : Des 199 extraits d’ADN initiaux, 173 (87%) 
étaient modifiés au bisulfite avec succès. Des ces spécimens modifiés, 71 (41%) ont 
démontré une hyperméthylation du MGMT. Pour les cas de méthylation et non-
méthylation du MGMT, les caractéristiques des patients n’étaient pas 
significativement différentes. Les taux de réponse étaient 71 et 73% (p=NS) 
respectivement. Le contrôle locorégional était respectivement 87 et 77% (p=0.26), la 
survie sans maladie était 80 et 60% (p=0.38), la survie sans métastase à distance était 
92 et 78% (p=0.08) et la survie globale était 64 et 62% (p=0.99) à 3 ans. 
Conclusions : L’état de méthylation du MGMT est fortement prévalent (41%) et 
semble avoir un possible impact bénéfique sur la survie quand la chimioradiothérapie 
est administrée aux patients avec des stades avancés de cancers tête et cou. 
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ENGLISH ABSTRACT  
 
Background: The O6-methylguanine-DNA methyltransferase (MGMT) gene encodes 
a specific DNA repair enzyme that protects cells from toxicity of alkylating agents. 
Thus, MGMT activity is a major mechanism of resistance to alkylating drugs. It has 
been shown that decreased MGMT gene expression by promoter hypermethylation 
results in improved survival in patients with certain types of tumors that are treated 
with alkylating chemotherapeutic agents. Objectives: To determine the prevalence of 
MGMT methylation in patients with locally advanced Head and Neck Squamous Cell 
Carcinoma (HNSCC) treated with chemoradiation therapy and to evaluate the impact 
of this methylation on survival. Methods: Out of 428 consecutive patients treated 
with chemoradiation therapy at our institution and followed for a median of 37 
months, 199 paraffin embedded biopsy or surgical specimens were retrieved. DNA 
was extracted and subjected to bisulfite treatment. A methylation specific PCR 
(MSP) was conducted to assess the methylation status of the MGMT gene promoter. 
Laboratory data was correlated with clinical response. Statistical analysis was 
performed using Fisher’s test for categorical data and Kaplan-Meier’s curves and log-
rank statistics for failure times. Results: From the initial 199 DNA extracts, 173 
(87%) were successfully modified with bisulfite. Out of these, 71 (41%) 
demonstrated hypermethylation of MGMT. For MGMT methylated cases and non-
methylated cases, patients characteristics were not significantly different. Response 
rates were 71 and 73% (p=NS), respectively. Local control rate (LCR) was 
respectively 87 and 77% (p=0.26), Disease-free survival (DFS) was 80 and 60% 
(p=0.38), distant metastasis free survival (DMFS) was 92 and 78% (p=0.08) and 
overall survival (OS) was 64 and 62% (p=0.99) at 3 years respectively. Conclusions: 
MGMT methylation status is highly prevalent (41%) and seems to have a possible 
beneficial impact on survival when chemoradiation therapy is given to patients with 
advanced stage HNSCC. 
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1. INTRODUCTION 
 
1.1 HNSCC demographics, treatment and prognosis 
 
Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most 
common human neoplasm with 50 000 new malignancies diagnosed each year in the 
United States, representing 5% of all cancer patients. In spite of current available 
treatment modalities, survival rates remain low around 50% at 5 years.1,2  
 
Initial patient evaluation includes assessment of histology, tumour grading, 
local invasion, lymph node metastasis status, and presence of distant metastasis. 
Treatment for these malignancies generally mainly consists of a single modality 
(surgery or radiation) for early stage disease and bimodality (surgery and radiation or 
chemotherapy and radiation) for advanced stage disease. Despite the advent of these 
radical treatments, survival rates for these tumours have not changed significantly 
over the last 30 years. 
 
Despite common histology and presentation, it remains unclear as to why 
HNSCC is associated with widely varying clinical behaviours and responses to 
therapy.3 Thus, clinicians are in need of tools to identify patients at high risk of poor 
outcome and to ultimately be able to predict response to therapy. Current research 
efforts focus on improving existing treatment modalities through molecular-based 
technologies. The goals are maximizing tumour control and minimizing unnecessary 
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toxicities, while allowing maximal organ preservation. This is better achieved when 
patient stratification by tumour characteristics is achieved.   
  
1.2 Genetic alterations 
 
It is now well documented that HNSCC is the result of a multi-hit mechanism 
occurring at different levels in the genes. Progressive accumulation of alterations that 
lead to activation of oncogenes or inactivation of tumour suppressor genes will 
trigger tumour development.4 Both genetic as well as epigenetic alterations have been 
implicated in HNSCC. Genetic alterations are ones that alter the gene sequence, 
affecting thus its normal expression. Common known genetic alterations in head and 
neck carcinogenesis are depicted in table I.  
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Table I – Common genetic alterations in head and neck carcinogenesis 
 
Nagai MA. Genetic alterations in head and neck squamous cell carcinomas. Braz J 
Med Biol Res. 1999; 32:897-904 
 
1.3 Epigenetic alterations 
 
Epigenetic changes are the ones that alter gene expression without changing 
the gene sequence itself. A specific change in the promoter region of a gene will 
affect its expression and is considered as an epigenetic event. The best example is 
morphogenesis in the mammalian embryo where totipotent stem cells differentiate 
into organs – that have genetically identical cells.5,6  
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A well known epigenetic alteration is that of hypermethylation of a gene’s 
promoter region. When this occurs, there is a change in the 3D configuration of DNA 
that will hinder gene function, decreasing protein expression. Hypermethylation of 
CpG islands of a promoter region is a known and frequent event in carcinogenesis.7 
Table II depicts common methylated genes in head and neck cancer.  
 
Table II –Common methylated tumour suppressor genes in head and neck cancer 
 
Ha PK, Califano JA. Promoter methylation and inactivation of tumour-suppressor 
genes in oral squamous-cell carcinoma. Lancet Oncol. 2006; 7(1):77-82 
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1.4 MGMT gene function and inactivation 
 
The MGMT gene is located at locus q26, chromosome 10. This gene codes 
the MGMT protein (see figure 1), a specific DNA repair enzyme that is ubiquitously 
expressed in normal human tissue. Although its exact physiologic function still to be 
fully defined, MGMT is known to restore DNA structure to its normal state by 
transferring aberrantly added methyl or alkyl groups from the O6-position of guanine 
to the enzyme’s active site. This restores guanine to its normal form preventing DNA 
strand breaks as shown in figure 2.  
 
Figure 1 – MGMT protein configuration 
 
www.dddc.ac.cn/group/Schwarzl/index.htm 
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Figure 2 – MGMT protein mechanism of action 
 
The Cell, fourth edition 
 
However, in tumour cells, this repair mechanism has a protective effect against cell 
death. In such conditions, the protein repairs DNA alterations incurred from toxicity 
of alkylating agents (i.e. chemotherapeutic agents) which frequently targets the O6 
position of guanine. By rapidly reversing these changes, the MGMT protein prevents 
thus the formation of lethal cross-links and other mutagenic effects.8,9 In that regards, 
MGMT activity is a major mechanism of resistance to alkylating drugs.10 Tumours 
expressing MGMT were found to be 4 to 10 times more resistant to chemotherapeutic 
drugs.11,12 Inactivation of the MGMT gene is known to occur by hypermethylation of 
 8 
 
the promoter region, leading to an under-expression of the protein that would 
normally repair lethal changes caused by alkylating chemotherapy drugs. 
 
1.5 Inactivation of MGMT in human neoplasia 
 
Recently, the gene encoding for the DNA repair enzyme MGMT has been 
found to be inactivated in several human cancers. Decreased expression was even 
observed in the precancerous states, as early as in leukoplakia and hyperplasia.13,14 
High rates (27%) of promoter hypermethylation were also found in normal 
surrounding mucosa in oral cancer patients.15,16 In vitro experiments showed 
decreased MGMT expression in cultured buccal mucosa epithelial cells from healthy 
individual, when exposed to tobacco extracts.17 In the head and neck literature, the 
status of MGMT inactivation was analysed in 13 different studies with a prevalence 
ranging from 18% to 56%.15,18,19,20,21,22,23,24,25,26,27,28,29 It is important to note that all 
these studies were carried out on a small number of patients (ranging from 30 to 99 
patients), except in one study by Dikshit et al. conducted on 235 patients with 
laryngeal and hypopharyngeal cancer.27 
 
Several studies have established that MGMT promoter hypermethylation 
and/or loss of MGMT gene expression are predictive of poor survival in cancer 
patients, namely: hepatocellular, gastric, lung, breast cancer as well as low-grade 
diffuse astrocystoma.30,31,32,33,34 Thus, it seems that MGMT promoter 
hypermethylation or loss of MGMT gene expression may represent an important 
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biomarker for biologically aggressive diseases in many human tumour types. On the 
other hand, it has also been shown in multiple studies that MGMT promoter 
hypermethylation resulting in a decreased MGMT gene expression improves survival 
in patients with malignant astrocytoma35, glioblastoma,36 glioma37 and diffuse large 
B-cell lymphoma,38 who were treated with alkylating chemotherapeutic agents, such 
as carmustine and temozolomide.  
 
1.6 MGMT methylation in HNSCC 
 
Although 13 cited studies relate the prevalence of MGMT in HNSCC, only 3 
correlate methylation status with patient survival. Zuo et al. found that MGMT 
promoter hypermethylation was a bad prognostic factor in 94 male subjects that were 
either treated surgically or medically.28 In an Indian study on 51 patients by Puri et 
al., it was found that promoter hypermethylation of at least 2 different genes 
(including MGMT) correlated with increased 2-year disease-free survival.26 A large 
multicentric case-control study conducted on 235 patients by Dikshit et al. showed 
that hypermethylation was not a predictor of mortality or second primary cancer.27 
However, the 3 above-mentioned studies contained heterogeneous groups of patients 
specifically in regards to tumour staging and treatment modalities. A more uniform 
study should generate results that are more representative of a specific group of 
patients. 
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We propose here a unique study in that regards: a large number of patients 
with only advanced stage HNSCC treated homogeneously with similar modalities 
(chemoradiation) at one single institution. We analysed the promoter 
hypermethylation pattern of the human MGMT gene in these tumours and studied the 
correlation with clinical features, namely, grade, toxicities, recurrences, as well as 
survival. 
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2. MATERIALS AND METHODS 
 
2.1 Tissue collection 
 
One hundred and ninety nine biopsy samples of primary tumours from paraffin 
blocks archives were collected from patients with HNSCC at our institution (Notre 
Dame University Hospital – CHUM, in Montreal, Canada) and from referring 
hospitals to our center between 1996 and 2002. All patients received treatment with 
subsequent follow-up at our University Hospital. For every patient, we conducted a 
retrospective chart review for assessment of patient’s characteristics, tumour staging, 
treatment modality, complications from treatment, survival and response rates to 
treatment.   
 
Inclusion criteria:  Locally advanced HNSSC, stages III and IV 
   Treatment with chemoradiation only 
   Minimum follow-up of 3 years 
 
Exclusion criteria:  Patients that had surgery before undergoing chemoradiation 
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2.2 DNA extraction  
(Annex 1)  
 
Three to ten 10-µm sections were cut from each paraffin-embedded pathology biopsy 
block. Paraffin was then washed by xylene and ethanol. Tissue was then degraded by 
proteinase K.  
 
2.3 Bisulfite treatment  
(Annex 2)  
 
DNA from tumour was subjected to bisulfite treatment. NaOH was used to denature 
DNA. Then DNA was modified by bisulfite and hydroquinone as described by Hegi 
et al.36 Unmethylated cytosine, but not its methylated counterpart, is modified into 
uracil by this treatment making thus the sequences distinguishable.  
 
2.4 Methylation Specific Polymerase Chain Reaction (MSP)  
(Annex 3)  
 
MSP was conducted to assess the methylation status of CpG island of MGMT gene 
promoter as previously described by Esteller et al.20,39 
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2.5 Agarose gel eletrophoresis  
(Annex 4)  
 
Amplicons were then migrated on agarose gel. They were then examined under UV 
light and a Polaroid picture was taken to assess for the presence or absence of the 
methylation status. See figure 3.  
 
Figure 3 – Gel electrophoresis 
 
U: Unmethylated 
M: Methylated 
 
 
 
 
 
 
 
 
 
U  M  U   M   U  M   U  M  U   M  U   M   U  M  U  M  U  M 
  1     2         3            4     5         6      7           8       H2O 
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2.6 Statistical Analysis 
 
Local control rate (LCR) was defined by the time elapsed from initial diagnosis to 
development of recurrent loco-regional disease. Overall survival (OS) was defined as 
total deaths by all causes. Disease-free survival (DFS) was the period of time from 
the initial diagnosis of tumour to the first sign of tumour recurrence. Distant 
metastasis free survival (DMFS) was the period of time free of distant metastasis. 
Response rate was defined as satisfactory regression of primary tumour and neck 
metastasis evaluated clinically and radiologically at 3 months after the end of 
treatments, which did not require salvage surgical therapy.  Survival functions were 
calculated using the Kaplan-Meier method. Logrank was used to compare the 
difference of survival curve between groups. Clinical correlation between 
methylation status and clinicopathological variables was determined using a Chi 
square test. 
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3. RESULTS 
 
Almost all tissues were derived from tumours without prior chemoradiation 
therapy. DNA extraction was performed on 199 tumour specimen. Adequate bisulfite 
modification was only achieved for 173 of the 199 tumours (87%). This is mainly 
due to the difficulty and rigorousness of the modification technique. DNA from 
paraffin-embedded tissues is more fragile than DNA from fresh tissues, explaining its 
degradation when submitted to bisulfite treatment. Table III depicts baseline patients’ 
characteristics.  
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3.1 Baseline characteristics of population 
 
 
 
  
Table III. Baseline characteristics      
  
  
Characteristic   No. of patients Percent 
  
  
Age (years)     
  
  
   Mean at diagnosis 56,4  
  
  
   Range   25 - 79  
  
  
      
  
  
Mean follow-up time (years) 2,5  
  
  
      
  
  
Sex     
  
  
   Male   133 76,9 
  
  
   Female   40 23,1 
  
  
      
  
  
Tumour site     
  
  
   Oropharynx 113 65,3 
  
  
   Larynx   28 16,2 
  
  
   Oral cavity  16 9,2 
  
  
   Hypopharynx 8 4,6 
  
  
   Unknown  5 2,9 
  
  
   Nose   3 1,7 
  
  
      
  
  
Tumour stage     
  
  
   III   30 17,3 
  
  
   IV    135 78,0 
  
  
   Recurrence 8 4,6 
  
  
      
  
  
Histopathologic grade   
  
  
   I (Well differentiated) 26 15,0 
  
  
   II (Moderately differentiated) 87 50,3 
  
  
   III (Poorly differentiated) 51 29,5 
  
  
IV (Undifferentiated) 0 0,0 
  
  
   Unknown  9 5,2 
  
            
 
 
Of 173 patients, 133 (76.9%) were males and 40 (23.1%) females. Average age at 
diagnosis was 56.4 years, ranging from 25 to 79 years. The mean follow up time was 
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37 months. The oropharynx was by far the most common tumour site with 113 
patients (65.3%). Other less common sites are larynx and oral cavity, representing 
16.2% and 9.2 % of tumours respectively. Stage IV disease was diagnosed in 135 
patients, representing 78%, whereas only 17.3% of patients had stage III, leaving the 
remaining 4.6% of our cohort with recurrent diseases. Staging was performed 
according to the TNM classification system from clinical and radiological 
assessment. Eighty seven patients had a moderately differentiated (grade 2) 
histopathological tumour grade, representing the majority with 50.3%. Grade 1 was 
described in 26 patients (15%) and grade 3 in 51 patients (29.5%), leaving 5.2 % of 
the specimens with an unknown grade.  
 
3.2 Treatment modalities 
 
Treatment modalities are illustrated in table IV. All patients, except one, 
received both radiation and chemotherapy. This single patient could not sustain the 
effects of chemotherapy due to weak general medical condition and was thus treated 
with radiation therapy alone. The usual radiation dose was 7000 cGy over an average 
period of 48 days and consisted of hyperfractionation. Chemotherapy was 
administered concomitantly to radiation therapy, according to 4 different regimens, 
the most common being carboplatinum with 5-Fluorouracil (5FU) given every 3 
weeks in 95 patients (54.9%).The remaining 77 patients (44.5%) received 
cisplatinum only given either daily, weekly or every 3 weeks. In 39 treated patients 
(19.7%) the tumour was found to be a second primary that was managed 
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independently with similar treatment modalities and conditions. These are the 
patients that have had HNSCC in the past and subsequently developed a second 
neoplasia that was not a recurrence.  
 
  
Table IV - Treatment modalities     
  
  
Characteristic Details No. of patients Percent 
  
  Radiation Therapy 7000 cGy over 48 days 173 100,0   
            
  Chemotherapy Concomitant  172 99,4   
    Carboplatinum & 5FU  Every 3 weeks 95 54,9   
    Cisplatinum Every 3 weeks 42 24,3   
    Cisplatinum Weekly 11 6,4   
    Cisplatinum  Daily 24 13,9   
            
  Second Primary      
    Yes  34 19,7   
    No  139 80,3   
            
 
3.3 MGMT methylation status 
 
MSP on 173 DNA samples revealed aberrant hypermethylation of the MGMT 
promoter in 71 patients (41%) with HNSCC as illustrated in Table V. This subgroup 
of 71 patients was representative of the overall population with respect to baseline 
patient characteristics as well as stage of the disease and treatment modalities. Also, 
positive and negative controls worked appropriately in all rounds of PCR reaction. It 
is important to note however, that we dealt with substantial sample contamination at 
the beginning of our experimentation. This mishap was early suspected, as we 
collected a strangely very high methylation status (close to 80%) of our specimen and 
obvious water contamination. The problem was initially seized and appropriate action 
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was achieved after we have realized that the pipettes were themselves contaminated. 
After serious repeated cleaning and sterilization of the instrumentation, we were 
confident in achieving reliable and consistent results that we have used in the current 
work. Methylation status was calculated following a non-quantitative assessment, 
i.e., we simply observed for the presence or the absence of the amplicons band in the 
MGMT MSP. We thus refrained from quantifying the amount of amplicon migration 
on the gel, since the technique we used is not one that can achieve quantifiable 
results. Therefore, interpretation of the results did not cause any possible confusion to 
the reader in almost all of the samples. Nonetheless, a third party was used to proof-
read the methylation status. In only 3 specimens, there was a discrepancy between 
both readers that was resolved by further examination until mutual agreement was 
reached. These specimens had very small amounts of amplicon that were barely 
readable on the Polaroid photograph. The final results from this data collection were 
then categorized as either positive or negative groups.  
 
 
 
 
 
  
Table V - Prevalence of MGMT methylation 
  
  
Status No. of patients Percent 
  
  
MGMT MSP + 71 41,0 
  
  
MGMT MSP -  102 59,0 
  
  
      
  
 20 
 
3.4 MGMT methylation status and correlation with clinical factors 
 
MGMT promoter hypermethylation was not found to be correlated with age, 
sex, tumour site, tumour stage, use of radiation therapy or chemotherapy. We found 
however a possible significant correlation between the methylated status and tumour 
grade as illustrated in Table VI. For grade I and II, there was almost equal number of 
patients in both groups MSP+ and MSP-. On the other hand, for grade III tumours, 
there were more than double the number of patients in the methylated group, in 
comparison with the unmethylated group (37 vs. 14 patients respectively), with a p 
value of 0.06. This finding suggests that poorly differentiated tumours tend to have 
the MGMT methylation more often that not.  
 
                    
  Table VI - Association of MGMT promoter methylation and      
  histopathological grade          
                    
  Tumour grade MGMT MSP +  MGMT MSP -  P value   
    No. %   No. %       
            
  I (Well differentiated) 13 7,5  13 7,5  NS   
  II (Moderately differentiated) 47 27,2  40 23,1  NS   
  III (Poorly differentiated) 37 21,4  14 8,1  0.06   
  IV (Undifferentiated) 0 0,0  0 0,0  -   
                    
  Abbreviation: NS, non-signficant          
                    
 
 Clinical correlation with complications from toxicities did not reveal any 
positive significant association with the methylated status. Variables tested included: 
gastrointestinal toxicities such as mucosititis, nausea, vomiting, weight loss, nasal 
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tube feeding or gastrostomy tube feeding; haematological and infectious toxicities 
such as decrease in haemoglobin count, platelet count, white blood cell count, febrile 
neutropenia or infection; and other toxicities such as need for hospitalisation, 
tracheostomy or death.  
 
 There were no significant differences between response rates to therapy in 
both groups (71% for the methylated group, vs. 73% for the unmethylated group, 
p=NS)).  
 
3.5 MGMT methylation status and survival 
 
Since most of HNSCC recurrences occur relatively early in the post treatment 
period, we used a 3-year survival analysis for our entire patient population. Table VII 
shows different forms of survival for both methylated and unmethylated groups.  
            
  Table VII - Effect of MGMT promoter status on patient survival   
        
  Survival at 3 years    Methylation status    
          
    MGMT MSP + (%) MGMT MSP - (%) P value   
  LCR 87 77 0,26   
  OS 64 62 0,99   
  DFS 80 60 0,38   
  DMFS 92 78 0,08   
            
  Abbreviations: LCR, local control rate, OS, overall survival,     
  DFS, disease free survival, DMFS, distant metastasis free survival.   
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When comparing methylated with unmethylated status, there was no 
significant difference for locoregional control at 3 years, representing a LCR of 87% 
vs. 77% (p=0,26). OS was also similar between both groups with 64% vs. 62% 
(p=0,99) respectively. There seemed to be a survival advantage of 20% with DFS 
between both groups, showing 80% vs. 60% respectively, although this was not 
statistically significant, with a p value of 0,38. (see figure 4) However, a survival 
advantage of 14% (92% vs 78% respectively) for DMFS has better statistical 
significance (p=0,08). (see figure 5) 
 
Figure 4 – Disease free survival 
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Figure 5 -  Distant metastasis free survival 
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4. DISCUSSION 
 
Predicting response to therapy in patients with HNSCC represents an active 
area of research in the current century. This study aimed to investigate MGMT 
hypermethylation status as a potential tumour marker in HNSCC. Methyaltion status 
was assessed in 173 patients treated with chemoradiation for advanced disease and 
correlation with clinical outcome was undertaken. Strengths of the current study 
include a large sample size that is homogeneous in regards to both stage of disease as 
well as treatment modality.  
 
The frequency of MGMT promoter hypermethylation in this study was 41%, 
fitting in the published range from 16% to 56% in 13 different reports. The largest 
study (235 patients) by Dikshit et al. demonstrated a frequency of 27%.27 The second 
largest (99 patients) is an Indian paper from Viswanathan et al. yielding also 41%. In 
another report by Zuo et al., hypermethylation was found in 18% of subjects. Most of 
the remaining articles were conducted on much smaller patient samples.28 Different 
factors could explain why our results are higher than those obtained by Dikshit and 
Zuo. First, we have different patient populations, in regards to racial aspects, as well 
as tumour site. Whereas larynx was the most common tumour for Diskshit, the oral 
cavity was dominant for Zuo. In our study, it is the oropharynx that represented the 
majority of cases. Also, different contributing etiologic factors might play a role. In 
our study, contamination could not have been responsible for the high percentage 
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observed, since successful controls were used in both bisulfite modification 
techniques as well as PCR techniques.  
  
Because of the clinical relevance of MGMT gene in oncology, we attempted 
to determine if MGMT hypermethylation would have an impact on clinical behavior 
in HNSCC patients. In the current study, 37 out or 51 tumors (72,5%) with a poorly 
differentiated histological grade expressed MGMT hypermethylation status, 
suggesting that high grade HNSCC tend to be rather methylated that not (p=0.06). 
These results are not sufficient to state that the poorer the tumour differentiation, the 
likelier the methylated status, since this trend was not observed in the moderately 
differentiated group. Our findings do not help in indicating neither that patients with 
a methylated MGMT tend to have a higher tumour grade.  
 
In our cohort of patients, we did not observe any correlation between studied 
toxicities and hypermethylation status of MGMT. No other reports in the literature 
studied this correlation for MGMT in HNSSC. It is intuitive for mucosal toxicities to 
be similar among both groups, since normal non-cancerous mucosa surrounding 
tumour is similar in both methylated and non-methylated groups.40  
 
Several cited studies herein have published that MGMT is both predictive of 
good and bad survival for different types of cancer. Only 3 papers discuss survival 
with MGMT in HNSSC, all with non-concordant results. We found a possible 
survival advantage for the hypermethylated group in regards to DFS (80% vs. 60%, 
 26 
 
p=0,38), and DMFS (92% vs. 78%, p=0,08) . Zuo et al.28 reported a decreased 2-year 
DFS for the hypermethylated group (38%) vs. 74% for the unmethylated group 
(p<0.01). Five-year cause specific survival (CSS) and OS were also significantly 
decreased (p<0.01). However, patient population was inhomogeneous for both 
patients’ characteristics and treatment modalities. This was also the first report to 
observe a correlation between MGMT hypermethylation and decreased MGMT 
protein expression in HNSSC. A study by Puri et al.26 does not support the findings 
previously described by Zuo et al.. Puri found an increased 2-year DFS (p=0,028) 
when 2 or 3 genes (p16, MGMT, hMLH1) were simultaneously hypermethylated, but 
not for patients with hypermethylation of only 1 gene. This paper also lacked 
homogeneity and was conducted on 51 samples. The latest report by Dikshit et al.27 is 
also the largest conducted on 235 patients with laryngeal and hypopharyngeal cancer. 
This group did not find a correlation between MGMT hypermethylation and survival. 
Although they were able to achieve better homogeneity in regards to tumour sites, 
patients with all 4 staged of disease were included and treatment modalities remained 
thus varied. The possible observed survival advantage in the methylated group 
undertaking chemoradiation therapy might be exaggerated by the presence of 
confounding factors, perhaps the concurrent presence of another genetic alteration. 
 
One of the limitations of this study pertains to our relatively small follow-up 
period. Although most HNSCC tend to recur in the early period following treatment, 
some will take years before reappearance, whether loco-regionally or distantly. 
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Following our cohort of patients for longer will allow a more accurate survival 
analysis, perhaps also helping towards achieving a better statistical significance.  
 
The MSP technique is designed to yield qualitative rather than quantitative 
methylation results. Absence of the amplicon band at the desired location on the 
migrated electrophoresis gel easily confirms that the specimen is lacking the 
methylated gene, i.e. is unmethylated. On the other hand, a frank white intense band, 
will confirm the methylated status. There exists, between these clear extremes, a full 
spectrum of intensities. Thus, with methylation specific PCR, one can only confirm 
or infirm the presence of methylation, without being able to quantify it. Other 
techniques of quantitative analysis, such as Real Time PCR have successfully been 
used to improve level of detection of methylation 41. However, in the current study, a 
methylated status was attributed to any presence of bands, regardless of intensity. 
This potentially means that the methylated group is comprised of tumours with 
different extents of methylation, making it heterogeneous in that regards. This could 
dilute the impact of the MGMT methylation in our clinical analysis. Also, if fresh 
instead of paraffin-embedded tissue samples were used, less DNA degradation would 
have ensued, allowing perhaps improved detection. Furthermore, our inclusion 
criteria aimed to achieve homogeneity in regards to type of tumour histology, 
staging, and modality of treatment. In spite of that, our cohort still contained different 
sites for HNSCC. However, this should not affect our results since both groups at 
study were comprised of similar patients’ characteristics.   
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In order to minimize variation of the quality of our measure and to control for 
possible ambiguity in interpretation of results, electrophoresis gel readings were done 
by 2 different independent operators, including one external to the study. Revisions 
and re-readings were undertaken on challenging instances until consensus was 
achieved unanimously.  
 
Moreover, provision of our tissue samples came from whole biopsy specimen 
present on the pathology sections, including thus tumour but also non-cancerous 
tissue surrounding it. This has additional potential dilutive effect, dampening the 
clinical outcome accounted by the methylated status. However, published articles 
advocate that normal tissue surrounding neoplastic tissue potentially harvests pre-
cancerous lesions. More interestingly, although this tissue might appear normal on 
histological exam, it was not on molecular biology testing. Specific molecular 
changes responsible for carcinogenesis and implicated in the multiple hit theory of 
cancer development were thus identified. In some of these studies, MGMT 
methylation was observed in mucosa with normal histology surrounding cancerous 
lesions.  This contradicts the hypothesis that the concentration of methylated MGMT 
gene is diluted by normal tissue surrounding the tumour. However other published 
reports, state the opposite. Righini et al.40 found that 90% of normal mucosa 
surrounding tumour specimen were free of methylation changes. The lack of 
consensus in that regards make conclusions difficult to draw.  
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Throughout our experiments, we encountered technical difficulties that 
necessitated much time and energy to rectify. Since parts of our experimentation 
were novel, we had to remodel existing protocols in the literature and create our own 
by trial and error, especially for bisulfite modification parameters (see Annex 2). The 
bisulfite modification is very lengthy and technically demanding. Despite meticulous 
work, it promotes DNA degradation, especially in paraffin-embedded tissue. This 
explains the non-interpretability of findings in 22 patients. Furthermore, we dealt 
with significant amounts of contamination during the first batches of bisulfite 
modification, hinted by aberrantly high (85%) methylation frequency in our 
population that was not concordant with the literature.  By isolating possible factors, 
we concluded that contamination originated from pipettes. After extensive cleaning 
and sterilization, we were able to achieve the current reliable results.   
 
This is the first study to report a possible survival advantage when only 
MGMT is hypermethylated in HNSCC. Its large sample size and homogeneous 
characteristics account for its strength. However, the possible observed survival 
advantage in this study in the methylated group undertaking chemoradiation therapy 
might have be exaggerated by the presence of confounding factors, perhaps the 
concurrent presence of another genetic alteration.  
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5. CONCLUSION 
 
MGMT methylation was a frequent event (41%) in our cohort of HNSSC 
patients. The presence of MGMT methylation might represent a positive survival 
advantage in advanced stage HNSSC patients treated with chemoradiation. 
Elucidation of genetic mechanisms and their role in development and behaviour of 
neoplasia will help better isolate individual genetic contributions. On the other hand, 
large cohorts of clinical studies will enlighten survival analysis pertaining to these 
genetic contributions. This will help confirming the MGMT methylation as a 
predictive factor to treatment. Ensuing patient stratification in regards to genetics will 
help better target a treatment while maximizing efficacy and minimizing undesirable 
side effects in HNSCC patients. More precisely, by determining the methylation 
status as part of a pre-operative patient assessment, physicians will better tailor 
chemoradiation therapy to patients that will benefit most from it, while reserving 
perhaps surgical options for those with less than ideal responses to medical treatment. 
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ANNEX 1 - DNA EXTRACTION FROM PARAFFIN EMBEDDED TISSUE 
SAMPLES 
 
1. Reagents  
 
 
1) Xylene  
2) Ethanol 100% 
3) Ethanol 95% 
3) Proteinase K (20 mg/ml, 20mg proteinase K + 1ml of buffer TEN, aliquot in 
20 µl and keep frozen at -20°C) 
4) Buffer TEN (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, 20 mM NaCl)  
 
2. Process 
 
 
1) Heat 3 to 10 pathology sections (depending on the size of tissue) per patient to 
72 °C for 1-3 minutes (Until the paraffin becomes transparent);  
2) Wash with xylene for 2 minutes, repeat 4 times;  
3) Wash with ethanol 100% for 1 minute, repeat 4 times;  
4) Wash with ethanol 95% for 1 minute, repeat 4 times;  
5) Prepare the digestion solution 1:100 (1µl of proteinase K in 99µl of buffer 
TEN); 
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6) Deposit (100 – 200 µl depending on tissue size) on a pathology section for 3 
minutes and scrape the tissue with a plastic instrument; 
7) Recover all the scrapings in an Eppendorf tube using a Pasteur pipette and 
incubate at 52 °C overnight; 
8) Inactivate proteinase K at  95 °C for exactly 3 minutes; 
9) Centrifuge at 12,000g for 20 minutes at 4 °C  and transvase the supernatant in 
a new Eppendorf tube. 
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ANNEX 2 - BISULFITE MODIFICATION OF DNA 
 
1. Reagents  
 
 
1) NaOH 6 M (6g of NaOH (FW 40.0) in 25 mL of deionized H2O, keep at 4°C 
to cool); 
2) NaOH 0.1M (50µl of NaOH 6 M + 2950µl of deionized H2O)(for 8 
specimens); 
3) Hydroquinone 100 mM (55 mg of hydroquinone (SIGMA#-9003, FW110.11) 
+ 5mL of deionized H2O, freshly prepared and keep at 4°C); 
4) Sodium Bisulfite 6.261 M at pH 5 (5.95g of bisulfite (SIGMA#-9000, 
FW190) + 8mL of  deionized H2O, ajust pH with 6M NaOH ~600-700µl , fill 
to 10 mL with H2O,  freshly prepared and keep at 4°C. Heat bisulfite in warm 
tap water and vortex for 20 minutes).               
 
2. Process 
 
1. Deposit 1.17µl of NaOH 6M in the tube; 
2. Add 33.83 µl of extracted DNA from paraffin-embedded tissue; 
3. Denature DNA at 37°C for 10 minutes; 
4. Spindown the tubes and add 253 µl of bisulfite first and then 72 µl of 
hydroquinone; 
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5. Incubate at 55 °C for 5h and brew 3 times during incubation. Then spindown the 
tubes; 
6. Add 150 µl of H2O in each tube;  
7. Transfer the diluted solution in a filter tube (Millipore, Genomics, UFC7PCR50) 
and centrifuge at 1200 xg for 10 minutes at 20°C; 
(Starting at this step, always close the tubes in the centrifugal machine to avoid 
contamination.) 
8. Add 350 µl of H2O to the tube, centrifuge at 1200 xg for 10 minutes at 20°C then 
elutriate the filtrate; 
9. Add 350 µl of NaOH 0.1M to the tube, at 1200 xg for 10 minutes at 20°C then 
elutriate the filtrate; 
10. Add 350 µl of H2O to the tube, centrifuge at 1500 xg for 15 minutes; 
11. Add 90 µl of H2O to the tube and incubate for 15 minutes at room temperature;  
12. Reverse the filter and put it in a new tube to collect the DNA; 
13. Centrifuge at 1000 xg for 5 min at 20°C; 
14. Keep DNA at - 20°C. 
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ANNEX 3 - METHYLATION SPECIFIC PCR (MSP) 
MSP is a specific type of Polymerase Chain Reaction that assesses the methylation 
status of groups of CpG sites within CpG islands  
1. Reagents  
Table VIII 
 
 
 
Reagents 
 
 
Quantity/tube 
 
Final concentration 
Buffer 10 X with MgCl2 15 mM 5 µl 1 X 
dNTPs 2mM 5 µl 0.2 mM 
MgCl2 25 mM 2 µl 1.8 mM 
*Primer MGMT-MF(10x) 5 µl 0.5 µM 
*Primer MGMT-MR (10x) 5 µl 0.5 µM 
Hotstart TAQ (Qiagen) 0.5 µl 2.5 u 
Q solution 10 µl  
BSA 1µl  
DNA 16.5  µl  
 
* 2 sets of primers are used in the preparation as depicted in table IX, as described 
previously.42 
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2. Sets of primers 
 
  
Table IX - Primer sequences for methylation-specific polymerase chain reaction analysis 
      
  Gene Sense primer, 5'→3' Antiense primer, 5'→3' 
Product 
size, bp AT, °C   
              
  MGMT M TTTCGACGTTCGTAGGTTTTCGC GCACTCTTCCGAAAACGAAACG 80 59   
  
MGMT U TTTGTGTTTTGATGTTTGTAGGTTTTTGT AACTCCACACTCTTCCAAAAACAAAACA 94 59   
              
  
Abbreviations: Bp indicates base pairs; AT, annealing temperature; M, methylated sequence;  
                        U, unmethylated sequence      
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3. PCR program  
 
 
96 °C 5 minutes 
  94 °C 30 seconds 
  50 °C 30 seconds          X 40 cycles 
  72 °C 30 seconds             
  72 °C 10minutes  
4°C→ end 
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ANNEX 4 - AGAROSE GEL ELECTROPHORESIS 
 
1) Pour 2 grams of agarose powder in 100mL solution of (10mL of buffer Tris-
Bromate; EDTA 10X concentrate and 90 mL of H2O); 
2) Heat in the microwave until boiling; 
3) Add 5µL ethidium bromide to the boiling liquid; 
4) Pour in the migration plate and allow 20 minutes for polymerisation; 
5) Pour 1L solution of (100mL buffer Tris-Bromate EDTA 10X concentrate and 
900mL of H2O) in the electrophoresis machine;  
6) Place gel in machine;  
7) Charge the slots on the gel with a mix of 15 µL of DNA and 3 µL of loading 
buffer 6X (Also, use one slot for marker pUC19 MspI); 
8) Let migrate at 145 volts for 45 minutes; 
9) Examine the gel in the dark under ultraviolet light; 
10) Take a picture with the Polaroid. 
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